Considering China For Clinical Studies The Pharma and Biotech Perspective
Sponsored by:
Almost 50% of biopharma are con-sidering China for clinical studies because of vast patient pools, competitive approval pathways, and cost savings.
Sponsored by:
Sponsored by:
Almost 50% of biopharma are con-sidering China for clinical studies because of vast patient pools, competitive approval pathways, and cost savings.
Sponsored by: